{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:53:21Z","timestamp":1790502801895,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,18]],"date-time":"2015-04-18T00:00:00Z","timestamp":1429315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12879-015-0913-0","type":"journal-article","created":{"date-parts":[[2015,4,17]],"date-time":"2015-04-17T00:24:32Z","timestamp":1429230272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Pouya","family":"Azar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxo","family":"Luma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-J","family":"Milloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,18]]},"reference":[{"key":"913_CR1","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1093\/ije\/dyp294","volume":"38","author":"M Zwahlen","year":"2009","unstructured":"Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol. 2009;38:1624\u201333.","journal-title":"Int J Epidemiol"},{"key":"913_CR2","first-page":"289","volume":"38","author":"E Wood","year":"2005","unstructured":"Wood E, Hogg RS, Yip B, Harrigan PR, Montaner J. Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy? J Acquir Immune Defic Syndr. 2005;38:289\u201395.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","volume":"133","author":"DL Paterson","year":"2000","unstructured":"Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21\u201330.","journal-title":"Ann Intern Med"},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/S0140-6736(03)15022-2","volume":"362","author":"SG Deeks","year":"2003","unstructured":"Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362:2002\u201311.","journal-title":"Lancet"},{"key":"913_CR5","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1111\/j.1360-0443.2008.02269.x","volume":"103","author":"M Malta","year":"2008","unstructured":"Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus\/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103:1242\u201357.","journal-title":"Addiction"},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1080\/13556219971704","volume":"4","author":"MP Carrieri","year":"1999","unstructured":"Carrieri MP, Tamalet C, Vlahov D, Yahi N, Chesney M, Moatti JP. Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users. Addict Biol. 1999;4:197\u2013202.","journal-title":"Addict Biol"},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.lfs.2010.09.025","volume":"88","author":"GM Lucas","year":"2011","unstructured":"Lucas GM. Substance abuse, adherence with antiretroviral therapy, and clinical outcomes among HIV-infected individuals. Life Sci. 2011;88:948\u201352.","journal-title":"Life Sci"},{"key":"913_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.280.6.547","volume":"280","author":"SA Strathdee","year":"1998","unstructured":"Strathdee SA, Palepu A, Cornelisse PG, Yip B, O\u2019Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547\u20139.","journal-title":"JAMA"},{"key":"913_CR9","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jama.300.5.550","volume":"300","author":"E Wood","year":"2008","unstructured":"Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BDL, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300:550\u20134.","journal-title":"JAMA"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.292.10.1175-b","volume":"292","author":"E Wood","year":"2004","unstructured":"Wood E, Hogg RS, Bonner S, Kerr T, Li K, Palepu A, et al. Staging for antiretroviral therapy among HIV-infected drug users. JAMA. 2004;292:1175\u20137.","journal-title":"JAMA"},{"key":"913_CR11","doi-asserted-by":"publisher","first-page":"F59","DOI":"10.1097\/00002030-199708000-00001","volume":"11","author":"SA Strathdee","year":"1997","unstructured":"Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;11:F59\u201365.","journal-title":"AIDS"},{"key":"913_CR12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00002030-200304110-00014","volume":"17","author":"MW Tyndall","year":"2003","unstructured":"Tyndall MW, Currie S, Spittal P, Li K, Wood E, O apos Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17:887\u201393.","journal-title":"AIDS"},{"key":"913_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.drugalcdep.2006.02.003","volume":"84","author":"A Palepu","year":"2006","unstructured":"Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, et al. Antiretroviral adherence and HIV treatment outcomes among HIV\/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84:188\u201394.","journal-title":"Drug Alcohol Depend"},{"key":"913_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1473-3099(05)70162-6","volume":"5","author":"E Wood","year":"2005","unstructured":"Wood E, Hogg RS, Harrigan PR, Montaner JSG. When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients. Lancet Infect Dis. 2005;5:407\u201314.","journal-title":"Lancet Infect Dis"},{"key":"913_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","volume":"139","author":"E Wood","year":"2003","unstructured":"Wood E, Hogg RS, Yip B, Harrigan PR, O\u2019Shaughnessy MV, Montaner JSG. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells\/L. Ann Intern Med. 2003;139:810\u20136.","journal-title":"Ann Intern Med"},{"key":"913_CR16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/135965350400900218","volume":"9","author":"E Wood","year":"2004","unstructured":"Wood E, Montaner JSG, Yip B, Tyndall MW, Schechter MT, O\u2019Shaughnessy MV, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther. 2004;9:229\u201335.","journal-title":"Antivir Ther"},{"key":"913_CR17","doi-asserted-by":"publisher","first-page":"a012104","DOI":"10.1101\/cshperspect.a012104","volume":"3","author":"SS Negus","year":"2013","unstructured":"Negus SS, Banks ML. Medications development for opioid abuse. Cold Spring Harb Perspect Med. 2013;3:a012104\u20134.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"913_CR18","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.drugpo.2006.12.014","volume":"18","author":"B Spire","year":"2007","unstructured":"Spire B, Lucas GM, Carrieri MP. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST). Int J Drug Policy. 2007;18:262\u201370.","journal-title":"Int J Drug Policy"},{"key":"913_CR19","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","volume":"281","author":"EC Strain","year":"1999","unstructured":"Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA. 1999;281:1000\u20135.","journal-title":"JAMA"},{"key":"913_CR20","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0140-6736(10)60832-X","volume":"376","author":"D Wolfe","year":"2010","unstructured":"Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376:355\u201366.","journal-title":"Lancet"},{"key":"913_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.drugalcdep.2014.03.025","volume":"139","author":"AW Carrico","year":"2014","unstructured":"Carrico AW, Woolf-King SE, Neilands TB, Dilworth SE, Johnson MO. Stimulant use and HIV disease management among men in same-sex relationships. Drug Alcohol Depend. 2014;139:174\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"913_CR22","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/09540120802385579","volume":"21","author":"C Marquez","year":"2009","unstructured":"Marquez C, Mitchell SJ, Hare CB, John M, Klausner JD. Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006. AIDS Care. 2009;21:575\u201382.","journal-title":"AIDS Care"},{"key":"913_CR23","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/09540120310001618621","volume":"15","author":"CJ Reback","year":"2003","unstructured":"Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care. 2003;15:775\u201385.","journal-title":"AIDS Care"},{"key":"913_CR24","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1517\/14656560903176446","volume":"10","author":"CA Hughes","year":"2009","unstructured":"Hughes CA, Robinson L, Tseng A, MacArthur RD. New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Expert Opin Pharmacother. 2009;10:2445\u201366.","journal-title":"Expert Opin Pharmacother"},{"key":"913_CR25","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1310\/hct0805-282","volume":"8","author":"F Maggiolo","year":"2007","unstructured":"Maggiolo F, Airoldi M, Kleinloog HD, Callegaro A, Ravasio V, Arici C, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials. 2007;8:282\u201392.","journal-title":"HIV Clin Trials"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-015-0913-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0913-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-015-0913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T07:48:53Z","timestamp":1651736933000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-015-0913-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,18]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1186\/s12879-015-0913-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,18]]},"assertion":[{"value":"29 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"193"}}